In addition to his work with the Company, Dr. Rohrer is also an Associate Professor within the Department of Immunology at the USA.  He graduated with a B.A. in Zoology from the University of Kansas in 1969 and received his Ph.D. in Microbiology from the University of Kansas in 1975.  He carried out his postdoctoral study at Washington University School of Medicine in the Fellowship and a Leukemia Society of America Special Fellowship during his post doctoral training.  He joined the faculty at the University of South Alabama college of Medicine in 1979.

Dr. Rohrer has exhaustively researched and published on the Onocfetal Antigen as well as characterizing the T and B lymphocyte response to immature laminin receptor protein (iLRP) during tumorigenesis.  Dr. Rohrer has played a central role in developing the Company’s cancer vaccine utilizing the OFA/iLRP as a target antigen for the Company’s dendritic cell therapy currently being tested in the FDA-authorized trials.